# Akebia Therapeutics, Inc. (AKBA): Investor Outlook with a Compelling 244% Potential Upside

- Link: https://www.directorstalkinterviews.com/akebia-therapeutics-inc-akba-investor-outlook-with-a-compelling-244-potential-upside/4121257641
- Published: 2026-07-24T10:19:22+01:00
- Author: Madison Wilson

Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical company headquartered
in Cambridge, Massachusetts, is capturing investor attention with its significant
potential upside. With a market capitalization of $327.28 million, Akebia operates
in the healthcare sector, specifically focusing on the development and commercialization
of therapies for kidney diseases. Its product lineup includes Vafseo (vadadustat)
and Auryxia, both of which target anemia and iron deficiency in chronic kidney disease
patients.

The current stock price of Akebia stands at $1.22, with a slight dip of 0.03% recently.
Notably, the stock has experienced a wide 52-week range between $0.87 and $3.84,
suggesting a volatile yet potentially rewarding investment opportunity. Analysts
have set a target price range of $3.00 to $6.00, with an average target of $4.20,
indicating a potential upside of 244.26%. This bullish sentiment is reinforced by
five buy ratings and no hold or sell recommendations.

Despite the promising analyst outlook, investors should be aware of certain financial
challenges. The company’s revenue growth has contracted by 6.60%, and its earnings
per share (EPS) is currently at -0.08. Furthermore, a return on equity of -78.96%
highlights the company’s struggle to generate profits from its equity base. However,
Akebia’s free cash flow of $65.8 million provides a cushion for ongoing operations
and potential strategic investments.

Valuation metrics reveal some areas of concern, with a forward P/E ratio of -6.42,
indicating expectations of continued losses in the near term. Additionally, traditional
valuation measures like the PEG ratio, price/book, and price/sales are not applicable,
often a red flag for investors seeking stability. However, for those willing to 
embrace risk, the lack of dividends and a payout ratio of 0% might not be a deterrent,
especially given the company’s focus on reinvesting in growth and development.

From a technical perspective, Akebia’s 50-day moving average sits at $1.12, while
the 200-day moving average is higher at $1.52. With a relative strength index (RSI)
of 36.83, the stock is nearing oversold territory, potentially presenting a buying
opportunity for those looking to capitalize on market corrections. The MACD indicator
at 0.05, with a signal line of 0.07, suggests a cautious stance as the stock seeks
to find its footing in a competitive market.

Akebia Therapeutics’ strategic collaborations and licensing agreements with entities
like Tanabe Pharma Corporation and CSL Vifor are key drivers for its international
expansion, particularly in Asian markets. The company’s ongoing development of AKB-
9090 and AKB-10108 could further enhance its portfolio, offering additional avenues
for growth and diversification.

Investors considering Akebia Therapeutics should weigh the high potential upside
against the inherent risks associated with its current financial position. While
the pathway to profitability remains challenging, the company’s innovative approach
to addressing kidney disease and strategic partnerships position it as a compelling,
albeit speculative, investment in the biopharmaceutical landscape.

Share on:
